FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Workshop on Generic Regulatory Science Initiatives

Federal Register notice: FDA announces a 5/24 public workshop on FY 2018 Generic Drug Regulatory Science Initiatives.

Federal Register

Joint Panel to Discuss Celebrex Safety Data

Federal Register notice: FDA announces a 4/24-25 joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting to ...

Human Drugs

Foundation Medicine Cancer Diagnostic Approved

FDA approves Foundation Medicines FoundationOne CDx (F1CDx), a next generation sequencing-based in vitro diagnostic test that can detect genetic mutat...

Human Drugs

FDA Releases 2 User Fee Implementation Plans

FDA has released two user fee-related implementation plans one on resource capacity and the other on updated benefit-risk assessments.

Human Drugs

Sunovion NDA Filed for Parkinsons Off Episodes

Sunovion Pharmaceuticals files an NDA for APL-130277 (apomorphine) sublingual film, indicated for treating motor fluctuations (Off episodes) in patien...

Medical Devices

Panel Backs Senseonics Continuous Glucose Monitor

FDAs Clinical Chemistry and Clinical Toxicology Devices Advisory Committee votes unanimously to recommend approval of Senseonics Holdings Eversense, a...

Federal Register

Joint Advisory Panel to Meet on Pain Drug NDA

Federal Register notice: FDA announces a 5/22 joint Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advi...

Human Drugs

Judge Orders Riddhi USA to Stop Product Sales

A New York federal judge approves an FDA consent decree with dietary supplement manufacturer and wholesaler Riddhi USA.

Federal Register

Revised Draft Guide for Generic Doxycycline Hyclate

Federal Register notice: FDA makes available a revised draft guidance on generic doxycycline hyclate oral delayed-release tablets, entitled Product-Sp...

Human Drugs

11 Observations from SCA Pharmaceuticals Inspection

FDA releases an FDA-483 with 11 observations from a recent inspection at SCA Pharmaceuticals.